Compare Amgen, Inc. (AMGN) vs Revvity Inc (RVTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Revvity Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Revvity Inc trades at $111.52 (market cap $12.53B). The key difference: Amgen, Inc. is far larger — about 15.7× Revvity Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | RVTY | |
|---|---|---|
Market Cap | $196.12B | $12.53B |
Sector | Health | Technology |
52-Week High | $388.16 | $117.75 |
52-Week Low | $271.18 | $82.26 |
Enterprise Value | $241.41B | $15.02B |
Dividend Yield | 2.77% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Revvity (RVTY) trades at $112.29, down 0.58% on the day, with strong technical momentum showing bullish moving averages and key support at $110. The company demonstrates consistent earnings beats with Q1 2026 EPS of $1.06 exceeding expectations, maintaining solid profitability with 54.32% gross margins. Recent developments include AI integration partnerships with Anthropic and FDA clearance for new diagnostic tests, signaling innovation in life sciences.
RVTY presents a mixed outlook with analyst consensus leaning bullish (52% buy ratings) but trading above the $109.38 price target. While strong operational cash flow ($583M in 2025) and AI expansion provide upside potential, elevated P/E ratio (53.99) and declining net cash flow (-$243M in 2025) warrant caution amid competitive pressures in healthcare technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
